Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

NCT06678074 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

STEMI
STEMI (ST Elevation MI)
STEMI - ST Elevation Myocardial Infarction (MI)
Stent Implantation

Interventions

DRUG: Atibuclimab (IC14), 20 mg/kg intravenously, once
OTHER: Placebo, 150 mL intravenously, once

Sponsor

Implicit Bioscience

Collaborators

[object Object]
[object Object]